{"id":"W3081807968","doi":"10.3310/hta24400","title":"Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT","year":2020,"lang":"en","type":"article","venue":"Health Technology Assessment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Economics","funders":"National Institute for Health and Care Research; Cancer Research UK; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; Daiichi Sankyo Europe; Health Technology Assessment Programme; Genentech; Servier; Pfizer; Eisai; Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical endpoint; Internal medicine; Randomized controlled trial; Oncology; Metastatic breast cancer; Adjuvant; Cancer; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02226211,0.002268184,0.0043263,0.0008317953,0.0006517295,0.002120796,0.001155748,0.004735866,0.01099542],"category_scores_gemma":[0.03276666,0.0008727001,0.007907086,0.0008341466,0.002036961,0.002916497,0.001458514,0.003862395,0.001130453],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001563958,"about_ca_system_score_gemma":0.002147487,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001002106,"about_ca_topic_score_gemma":0.001591853,"domain_scores_codex":[0.9727027,0.02191415,0.002279355,0.001361916,0.000906767,0.0008350877],"domain_scores_gemma":[0.9832442,0.01003175,0.003562363,0.001571046,0.0008064319,0.0007842062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9521069,0.002797769,0.001104319,0.009258199,0.009905307,0.0001521729,0.0003385329,0.000383387,0.0008428242,0.001008426,0.001080577,0.02102165],"study_design_scores_gemma":[0.9582463,0.02743705,0.001315331,0.001247434,0.00651384,0.00007388571,0.0001049403,0.0003223204,0.0002727658,0.001847632,0.002582793,0.00003575446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8230324,0.08577117,0.008677415,0.007409775,0.007134213,0.05058007,0.00247821,0.0002882853,0.0146284],"genre_scores_gemma":[0.9421372,0.008227028,0.007071606,0.004770793,0.001451424,0.0303151,0.0005567493,0.00004655571,0.0054236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02226211,"threshold_uncertainty_score":0.1177347,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02579314638784396,"score_gpt":0.3727333279500021,"score_spread":0.3469401815621582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}